Italy-based Stevanato has teamed up with Owen Mumford to provide customers with a two-step, single-use auto-injector that automatically adapts to a range of fill volumes. The agreement sees Stevanato become the exclusive manufacturing partner for Owen Mumford’s Aidaptus auto-injector. In that capacity, Stevanato will mould components, provide final and sub-assembly equipment and offer prefilled syringes to customers. 

Mauro Stocchi, Chief Business Officer, Stevanato, called the agreement an 'important step' in the company’s drug delivery strategy, adding that it is continuing to see increased demand for auto-injectors. Owen Mumford thinks Aidaptus has advantages over rival auto-injectors.  

“This auto-injector can help reduce complexity, minimise supply chain risk and simplify final assembly for pharmaceutical and biotechnology companies, thanks to its ability to adapt to different viscosity, syringe sizes and fill volumes. Often during the development or life-cycle management of injectable drug products, changes in these parameters can occur. Now for the first time, the device does not have to be changed as well,” Adam Mumford, Director, Owen Mumford, said.

Other features are intended to improve the patient experience. Owen Mumford has sought to reduce the size and weight of the device while adding features such as an audible click at the start and end of each injection to make it easier for patients to carry and use Aidaptus.